These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10511603)

  • 21. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
    Look AT
    J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
    [No Abstract]   [Full Text] [Related]  

  • 22. Ancient remedy performs new tricks.
    Mervis J
    Science; 1996 Aug; 273(5275):578. PubMed ID: 8701308
    [No Abstract]   [Full Text] [Related]  

  • 23. Scientists explore use of arsenic in therapy.
    Miller M
    J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
    [No Abstract]   [Full Text] [Related]  

  • 24. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells.
    Park JW; Choi YJ; Jang MA; Baek SH; Lim JH; Passaniti T; Kwon TK
    Biochem Biophys Res Commun; 2001 Aug; 286(4):726-34. PubMed ID: 11520058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
    Wang HX; Duan LN; Ji SQ; Guo ZK
    Leuk Lymphoma; 2006 Jul; 47(7):1438-40. PubMed ID: 16923589
    [No Abstract]   [Full Text] [Related]  

  • 26. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Au WY; Tam S; Kwong YL
    Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
    [No Abstract]   [Full Text] [Related]  

  • 27. Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
    Fung TK; So CW
    Oncotarget; 2013 Aug; 4(8):1128-9. PubMed ID: 23934744
    [No Abstract]   [Full Text] [Related]  

  • 28. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
    Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
    Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
    Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
    [No Abstract]   [Full Text] [Related]  

  • 30. Co-biomodulation with arsenic trioxide in multiple myeloma.
    Gallagher RE
    Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
    [No Abstract]   [Full Text] [Related]  

  • 31. Arsenic compound approved as cancer chemotherapy agent.
    Miller JL
    Am J Health Syst Pharm; 2000 Nov; 57(21):1940, 1942. PubMed ID: 11094644
    [No Abstract]   [Full Text] [Related]  

  • 32. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
    Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
    Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
    [No Abstract]   [Full Text] [Related]  

  • 33. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
    Zhu H; Hu J; Chen L; Zhou W; Li X; Wang L; Zhao X; Zhang Y; Zhao H; Wang A; Chen Y; Sun H; Chen Q; Chen Y; Zhao W; Mi J; Shen Z; Wang Z; Chen Z; Chen S; Li J
    Blood; 2016 Sep; 128(11):1525-8. PubMed ID: 27402972
    [No Abstract]   [Full Text] [Related]  

  • 34. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
    Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
    Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
    Huang SY; Chang CS; Tang JL; Tien HF; Kuo TL; Huang SF; Yao YT; Chou WC; Chung CY; Wang CH; Shen MC; Chen YC
    Br J Haematol; 1998 Dec; 103(4):1092-5. PubMed ID: 9886325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Arsenic trioxide: impact on the growth and differentiation of cancer cells and possible use in cancer therapy].
    Hoffman E; Mielicki WP
    Postepy Hig Med Dosw (Online); 2013 Aug; 67():817-27. PubMed ID: 24018447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
    Carney DA
    Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
    [No Abstract]   [Full Text] [Related]  

  • 38. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationship of arsenic trioxide and tumor cell apoptosis].
    Song J; Zhang DS
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Aug; 23(8):635-8. PubMed ID: 14503071
    [No Abstract]   [Full Text] [Related]  

  • 40. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.